Welcome to our dedicated page for ReWalk Robotics Ltd. news (Ticker: $RWLK), a resource for investors and traders seeking the latest updates and insights on ReWalk Robotics Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ReWalk Robotics Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ReWalk Robotics Ltd.'s position in the market.
Rhea-AI Summary
ReWalk Robotics Ltd. (Nasdaq: RWLK) issued an open letter from CEO Larry Jasinski to shareholders detailing transformational achievements in 2023 and commercial and operating priorities for 2024. Achievements include progress with Medicare, acquisition of AlterG, FDA clearance for ReWalk Personal Exoskeletons, and plans for 2024 commercial and operational priorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
-
Rhea-AI Summary
ReWalk Robotics, Ltd. (Nasdaq: RWLK) presented at the Healthcare Common Procedure Coding System public meeting and supported the proposed 'gap-filling' pricing method by CMS with up-to-date pricing information. The company provided feedback to CMS regarding the preliminary payment determination for the ReWalk Personal Exoskeleton. The CEO, Larry Jasinski, expressed appreciation for CMS's progress and provided updated pricing information to aid in payment calculations. CMS is expected to review the additional information and issue a final payment determination in February 2024, implementing payment rate updates to its fee schedule effective April 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
-
News
Rhea-AI Summary
ReWalk Robotics (Nasdaq: RWLK) successfully demonstrated a proof-of-concept next-generation exoskeleton integrating advanced sensing technologies and artificial intelligence. The company aims to make exoskeletons easier and safer to use, reducing cognitive load on the user and broadening the use case to more activities of everyday life. ReWalk collaborates with the Human Robot Interaction Consortium to develop advanced technologies for improving human-exoskeleton interaction, widening adoption and making the use of exoskeletons easier and more natural.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
Rhea-AI Summary
ReWalk Robotics Ltd. (Nasdaq: RWLK) announced record quarterly revenue of $4.4 million, completion of AlterG acquisition, and progress in attaining Medicare payment coverage for exoskeletons. The company highlighted significant achievements, including the acquisition of AlterG, progress with Medicare claim submissions, and advancements in the ReWalk 7 technology. Financially, revenue increased by 397% compared to Q3'22, with a gross margin of 19.6%. The company's liquidity stood at $32.6 million in unrestricted cash and cash equivalents with no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
-
Rhea-AI Summary
ReWalk Robotics Ltd. (Nasdaq: RWLK) commends the introduction of the Veterans Spinal Trauma Access to New Devices (STAND) Act, a bipartisan bill that aims to improve access to powered exoskeletons for clinically-eligible U.S. Veterans. The bill mandates annual exoskeleton evaluations, progress updates to Congress, involvement of manufacturers in clinical practice guideline changes, and inclusion of exoskeleton usage in performance metrics for VA leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
-
Rhea-AI Summary
ReWalk Robotics Ltd. schedules a conference call to discuss Medicare's preliminary payment determination for the ReWalk Personal Exoskeleton, with a preliminary payment determination of $94,617.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
Rhea-AI Summary
ReWalk Robotics Ltd. will release its third quarter 2023 financial results on November 14, 2023, and host a conference call and live webcast to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
-
News
Rhea-AI Summary
ReWalk Robotics announced that the Centers for Medicare & Medicaid Services (CMS) has included the ReWalk Personal Prosthetic Exoskeleton system in the agenda for the upcoming HCPCS meeting. CMS provided a preliminary payment determination of $94,617. ReWalk will participate in the meeting to ensure accurate Medicare payment rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
-
Rhea-AI Summary
ReWalk Robotics Ltd. announces the finalization of the 2024 Medicare Home Health Rule, which includes personal exoskeletons in the Medicare brace benefit category. This rule expedites access to exoskeleton technology for individuals with spinal cord injuries. The rule will go into effect on January 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
Rhea-AI Summary
ReWalk Robotics to present ReWalk Exoskeleton at GITEX GLOBAL event in Dubai
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
ReWalk Robotics Ltd.
Nasdaq:RWLK
RWLK Rankings
RWLK Stock Data
8.92M
58.82M
1.96%
20.72%
2.27%
Surgical and Medical Instrument Manufacturing
Manufacturing
Israel
P O Box 161
About RWLK
exoskeleton leader rewalk robotics, inc. (formerly argo medical technologies) develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury (sci). rewalk’s mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. founded in 2001, rewalk has headquarters in the us, israel and germany. rewalk robotics' rewalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury (sci) to stand upright and walk. rewalk is the only exoskeleton with fda clearance via clinical studies and extensive performance testing for personal use rewalk has been tested extensively in the u.s., europe, and israel. the rewalk system is supported by the most published data of all exoskeleton systems in the rehabilitation market, and is used by more people worldwide than all other exoskeleton systems combined. the company offers two products: rewalk personal and the